Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Journal of Medicinal Chemistry
|
January 5, 2018
Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors
Bin Yang, Melissa M Vasbinder, Alexander W Hird, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 3, 2005
Structure-based design of protein tyrosine phosphatase-1B inhibitors
Emma Black, Jason Breed, Alexander L Breeze, et al.
Molecular Cancer Therapeutics
|
February 14, 2024
Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates
Joshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 3, 2010
Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration
Vibha Oza, Susan Ashwell, Patrick Brassil, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 29, 2015
Identification of azabenzimidazoles as potent JAK1 selective inhibitors
Melissa M Vasbinder, Marat Alimzhanov, Martin Augustin, et al.
Journal of Medicinal Chemistry
|
July 24, 2023
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates
Jeremy R Duvall, Joshua D Thomas, Raghida A Bukhalid, et al.
Journal of Medicinal Chemistry
|
May 4, 2012
Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas
Vibha Oza, Susan Ashwell, Lynsie Almeida, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 13, 2008
Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors
James W Janetka, Lynsie Almeida, Susan Ashwell, et al.
Cancer Cell
|
January 15, 2016
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Cancer Cell
|
June 12, 2019
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Journal of Medicinal Chemistry
|
January 5, 2018
Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors
Bin Yang, Melissa M Vasbinder, Alexander W Hird, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 3, 2005
Structure-based design of protein tyrosine phosphatase-1B inhibitors
Emma Black, Jason Breed, Alexander L Breeze, et al.
Molecular Cancer Therapeutics
|
February 14, 2024
Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates
Joshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 3, 2010
Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration
Vibha Oza, Susan Ashwell, Patrick Brassil, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 29, 2015
Identification of azabenzimidazoles as potent JAK1 selective inhibitors
Melissa M Vasbinder, Marat Alimzhanov, Martin Augustin, et al.
Journal of Medicinal Chemistry
|
July 24, 2023
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates
Jeremy R Duvall, Joshua D Thomas, Raghida A Bukhalid, et al.
Journal of Medicinal Chemistry
|
May 4, 2012
Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas
Vibha Oza, Susan Ashwell, Lynsie Almeida, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 13, 2008
Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors
James W Janetka, Lynsie Almeida, Susan Ashwell, et al.
Cancer Cell
|
January 15, 2016
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Cancer Cell
|
June 12, 2019
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Page
of 3